Our business model is designed to bring solutions to patients while generating shareholder value, by translating our proprietary technology into commercial drug products in a rapid and cost-effective way.



Investment case

Silence is the only listed RNAi player in Europe and a pioneer in this technology. Through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger RNAi in specific cell types. Our inventions are protected by a broad intellectual property estate, which is a fundamental asset. Together with our progress, the fact that the field is generally maturing means that RNAi drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients.


Results, reports & presentations

AR18 pic.JPG

Annual Report 2018

Showing: All Size

Half Year Results 2019

345KB Download

Full Year Results 2018

371KB Download

Half Year Results 2018

367KB Download

Full Year Results 2017

298KB Download

Half Year Results 2017

154KB Download

Annual Report 2018

3MB Download

Annual Report 2017

2MB Download

Annual Report 2016

1MB Download

Annual Report 2015

978KB Download

Annual Report 2014

9MB Download

Silence Therapeutics Virtual Presentation at the Annual Needham Healthcare Conference - Live webcast

Click here to register for the webcast

800KB Download

Collaboration with AstraZeneca to Discover and Develop siRNA Therapeutics for Cardiovascular, Renal, Metabolic and Respiratory Diseases - Live presentation and Q&A

Click here to replay the webcast

509KB Download

Cowen Health Care March 2020 Silence Therapeutics Presentation

Click here for the webcast

1MB Download

JP Morgan January 2020 Corporate Presentation

1MB Download

Scientific Sessions 2019 - A Novel Short Interfering Ribonucleic Acid Shows Potent And Sustained Reduction Of Serum Lipoprotein(a) In Cynomolgus Monkeys

746KB Download

Corporate governance 

Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.


We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.